市場調查報告書

按治療,管理途徑,分銷渠道,區域規模,佔有率,前景,機會分析進行的斯蒂爾疾病治療市場

Still's Disease Treatment Market, by Treatment, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版商 Coherent Market Insights 商品編碼 952848
出版日期 內容資訊 英文 140 Pages
商品交期: 2-3個工作天內
價格
按治療,管理途徑,分銷渠道,區域規模,佔有率,前景,機會分析進行的斯蒂爾疾病治療市場 Still's Disease Treatment Market, by Treatment, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
出版日期: 2020年07月23日內容資訊: 英文 140 Pages
簡介

全球斯蒂爾氏病治療市場的增長得益於斯蒂爾氏病的流行和不斷增加的研發資金,以開發新的療法和療法。另外,用於治療斯蒂爾氏病相關併發症的治療劑的出現是推動市場增長的另一個因素。但是,一些中低收入國家缺乏醫療保健資金以及藥品專利到期是限制市場增長的一些關鍵因素。

本報告調查了全球Stille治療市場,並探討了市場機會和趨勢,增長和限制,Covid-19的影響,按治療進行的市場分析,管理途徑,分銷渠道和地區以及競爭。我們提供有關主要公司的狀況和概況的信息。

目錄

第1章調查目的和假設

第2章市場概述

  • 報告概述
    • 市場定義和範圍
  • 執行摘要
    • 市場細分:按治療
    • 市場細分:按管理途徑劃分
    • 市場細分:按分銷渠道
    • 市場細分:按地區
  • 相干機會圖(COM)

第3章市場動態,法規,趨勢分析

  • 市場動態
    • 生長因子
    • 抑制因子
    • 市場機會
  • 影響分析
  • 斯蒂爾氏病的治療技術進展
  • 主要發展
  • 收購,合作,合作
  • 流行病學
  • 管道分析
  • 品牌分析

第4章Covid-19的影響

  • Covid-19之前的狀態
  • Covid-19之後的需求
  • 需要進行Still病治療
  • 建議和準則:監管機構

第5章市場分析:按治療方式

  • 簡介
  • 疼痛管理
  • 皮質類固醇
  • 托珠單抗
  • 金魚菊
  • Anakinra
  • 其他

第6章市場分析:按管理途徑

  • 簡介
  • 注射
  • 口服

第7章市場分析:按分銷渠道

  • 簡介
  • 零售藥房
  • 醫院藥房
  • 在線藥房

第8章按地區進行市場分析

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 非洲
  • 中東

第9章競爭情況

  • 公司簡介
    • AB2 Bio Ltd.
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • Swedish Orphan Biovitrum AB
    • Jubilant Life Sciences Ltd
    • Vintage Labs
    • Hikma Pharmaceuticals PLC
    • Teva Pharmaceutical Industries Ltd
    • Mylan N.V.
    • Horizon Therapeutics plc
    • Sun Pharmaceutical Industries Ltd
    • Zydus Cadila
    • Amneal Pharmaceuticals LLC
    • Dr Reddy's Laboratories Ltd.
    • Fresenius Kabi AG

第10章的部分

目錄

Still's disease, also known as adult-onset Still's disease (AOSD), is a rare type of inflammatory disorder associated with joint pain, rash, and fevers. This devastating condition may lead to long-term chronic arthritis and can result in permanent disabilities. Still's disease is related to the rash that does not itch and high spiking fever. This disorder can destroy affected joints, mainly the wrists. The treatment of Still's disease involves medications that help inflammation.

Market Dynamics

The increase in funding for research and development to develop novel therapies and treatment coupled with increasing prevalence of Still's disease are the major factors boosting growth of the global still's disease treatment market. For instance, according to WebMD, Still's disease is more prevalent in women and affects less than 1 in 100,000 people across the globe develop Still's or adult-onset still's each year.

Moreover, the emergence of drugs for the treatment of complications related to Still's disease is another factor propelling the market growth. For instance, in July 2020, the U.S. Food and Drug Administration (FDA) expanded the use of Canakinumab (Ilaris) for all patients with active Still's disease older than 2 years. Therefore, the drug can now be used for the adult-onset Still's disease (AOSD), which was previously approved for only juvenile-onset Still's disease.

However, the lack of healthcare finance in some low- and middle-income countries and patent expiration of drugs are some of the major factors restricting growth of the global still's disease treatment market.

Key features of the study:

  • This report provides in-depth analysis of the global still's disease treatment market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains the attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global Still's disease treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
  • Key players covered as a part of this study include F. Hoffmann-La Roche Ltd, Swedish Orphan Biovitrum AB, Novartis AG, Jubilant Life Sciences Ltd, AB2 Bio Ltd., Hikma Pharmaceuticals PLC, Dr Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Mylan N.V., Zydus Cadila, Horizon Therapeutics plc, Amneal Pharmaceuticals LLC, Fresenius Kabi AG., and Vintage Labs
  • Insights from this report would allow marketers and management authorities of companies to make an informed decision with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global still's disease treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for Still's disease treatment market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Still's Disease Treatment Market, By Treatment:
    • Pain Management
    • Corticosteroids Therapy
    • Tocilizumab
    • Canakinumab
    • Anakinra
    • Others
  • Global Still's Disease Treatment Market, By Route of Administration:
    • Injectable
    • Oral
  • Global Still's Disease Treatment Market, By Distribution Channel:
    • Retail Pharmacies
    • Hospital Pharmacies
    • Online Pharmacies
  • Global Still's Disease Treatment Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
      • By Treatment:
    • Pain Management
    • Corticosteroids Therapy
    • Tocilizumab
    • Canakinumab
    • Anakinra
    • Others
      • By Route of Administration:
    • Injectable
    • Oral
      • By Distribution Channel:
    • Retail Pharmacies
    • Hospital Pharmacies
    • Online Pharmacies
    • Europe
      • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
      • By Treatment:
    • Pain Management
    • Corticosteroids Therapy
    • Tocilizumab
    • Canakinumab
    • Anakinra
    • Others
      • By Route of Administration:
    • Injectable
    • Oral
      • By Distribution Channel:
    • Retail Pharmacies
    • Hospital Pharmacies
    • Online Pharmacies
    • Asia Pacific
      • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
      • By Treatment:
    • Pain Management
    • Corticosteroids Therapy
    • Tocilizumab
    • Canakinumab
    • Anakinra
    • Others
      • By Route of Administration:
    • Injectable
    • Oral
      • By Distribution Channel:
    • Retail Pharmacies
    • Hospital Pharmacies
    • Online Pharmacies
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
      • By Treatment:
    • Pain Management
    • Corticosteroids Therapy
    • Tocilizumab
    • Canakinumab
    • Anakinra
    • Others
      • By Route of Administration:
    • Injectable
    • Oral
      • By Distribution Channel:
    • Retail Pharmacies
    • Hospital Pharmacies
    • Online Pharmacies
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
      • By Treatment:
    • Pain Management
    • Corticosteroids Therapy
    • Tocilizumab
    • Canakinumab
    • Anakinra
    • Others
      • By Route of Administration:
    • Injectable
    • Oral
      • By Distribution Channel:
    • Retail Pharmacies
    • Hospital Pharmacies
    • Online Pharmacies
    • Africa
      • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
      • By Treatment:
    • Pain Management
    • Corticosteroids Therapy
    • Tocilizumab
    • Canakinumab
    • Anakinra
    • Others
      • By Route of Administration:
    • Injectable
    • Oral
      • By Distribution Channel:
    • Retail Pharmacies
    • Hospital Pharmacies
    • Online Pharmacies
  • Company Profiles
    • F. Hoffmann-La Roche Ltd.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Swedish Orphan Biovitrum AB
    • Novartis AG
    • Jubilant Life Sciences Ltd
    • AB2 Bio Ltd.
    • Hikma Pharmaceuticals PLC
    • Dr Reddy's Laboratories Ltd.
    • Teva Pharmaceutical Industries Ltd
    • Sun Pharmaceutical Industries Ltd
    • Mylan N.V.
    • Zydus Cadila
    • Horizon Therapeutics plc
    • Amneal Pharmaceuticals LLC
    • Fresenius Kabi AG
    • Vintage Labs
  • "*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Treatment
    • Market Snippet, By Route of Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Technological Advancements in Still's Disease Treatment
  • Key Developments
  • Acquisition, Collaborations & Partnerships
  • Epidemiology
  • Pipeline Analysis
  • Brand Analysis

4. Global Still's Disease Treatment Market, Impact of Coronavirus (Covid-19) Pandemic

  • Pre-COVID situation
  • Post-COVID demand
  • Need for Still's Disease Treatment
  • Recommendations and Guidelines by Regulatory Bodies

5. Global Still's Disease Treatment Market, By Treatment, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Pain Management
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Corticosteroids
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Tocilizumab
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Canakinumab
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Anakinra
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

6. Global Still's Disease Treatment Market, By Route of Administration , 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Injectable
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

7. Global Still's Disease Treatment Market, By Distribution Channel, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

8. Global Still's Disease Treatment Market, By Region, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2020 and 2027(%)
    • Y-o-Y Growth Analysis, By Region, 2017 -2027
    • Regional Trends
  • North America
    • Market Size and Forecast, By Treatment, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Treatment, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Treatment, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Treatment, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Treatment, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa
  • Middle East
    • Market Size and Forecast, By Treatment, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East

9. Competitive Landscape

  • Company Profiles
    • AB2 Bio Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • F. Hoffmann-La Roche Ltd
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Novartis AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Swedish Orphan Biovitrum AB
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Jubilant Life Sciences Ltd
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Vintage Labs
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Hikma Pharmaceuticals PLC
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Teva Pharmaceutical Industries Ltd
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Mylan N.V.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Horizon Therapeutics plc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Sun Pharmaceutical Industries Ltd
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Zydus Cadila
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Amneal Pharmaceuticals LLC
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Dr Reddy's Laboratories Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Fresenius Kabi AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact